HK1066536A1 - Optical isomers of an iloperidone metabolite - Google Patents

Optical isomers of an iloperidone metabolite

Info

Publication number
HK1066536A1
HK1066536A1 HK04109446.7A HK04109446A HK1066536A1 HK 1066536 A1 HK1066536 A1 HK 1066536A1 HK 04109446 A HK04109446 A HK 04109446A HK 1066536 A1 HK1066536 A1 HK 1066536A1
Authority
HK
Hong Kong
Prior art keywords
optical isomers
iloperidone metabolite
fouoro
isoxazol
piperidin
Prior art date
Application number
HK04109446.7A
Other languages
English (en)
Inventor
Dominique Grimler
Hans O Kalkman
Hequn Yin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1066536A1 publication Critical patent/HK1066536A1/xx
Priority to HK11110560.6A priority Critical patent/HK1156309A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK04109446.7A 2001-08-31 2004-11-30 Optical isomers of an iloperidone metabolite HK1066536A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HK11110560.6A HK1156309A1 (en) 2001-08-31 2011-10-06 Optical isomers of an iloperidone metabolite

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Publications (1)

Publication Number Publication Date
HK1066536A1 true HK1066536A1 (en) 2005-03-24

Family

ID=23228843

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04109446.7A HK1066536A1 (en) 2001-08-31 2004-11-30 Optical isomers of an iloperidone metabolite
HK11110560.6A HK1156309A1 (en) 2001-08-31 2011-10-06 Optical isomers of an iloperidone metabolite

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11110560.6A HK1156309A1 (en) 2001-08-31 2011-10-06 Optical isomers of an iloperidone metabolite

Country Status (10)

Country Link
US (4) US20050020632A1 (de)
EP (2) EP1425272B1 (de)
JP (6) JP2005504783A (de)
AT (1) ATE518845T1 (de)
CY (2) CY1112039T1 (de)
DK (2) DK2305656T3 (de)
ES (2) ES2370634T3 (de)
HK (2) HK1066536A1 (de)
PT (2) PT2305656E (de)
WO (1) WO2003020707A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE493129T1 (de) 2001-10-30 2011-01-15 Novartis Pharma Gmbh Depot formulierungen von iloperidone und einem sternförmigen polymer
ATE398108T1 (de) 2002-03-27 2008-07-15 Glaxo Group Ltd Chinolinderivate und deren verwendung als 5-ht6 liganden
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
ES2258760T3 (es) 2003-07-22 2006-09-01 Arena Pharmaceuticals, Inc. Derivados de diaril y de la urea de arileteroaril usados como moduladores del receptor de la serotonina 5-ht2a utiles para la profilaxis y el tratamiento de desordenes a ellos asociados.
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
CA3113166A1 (en) * 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
EP2134873B1 (de) 2007-03-29 2015-05-06 Vanda Pharmaceuticals Inc. Verfahren zur prognose einer prädisposition für qt-verlängerung
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
ES2681240T3 (es) 2007-05-18 2018-09-12 Vanda Pharmaceuticals Inc. Marcadores genéticos de eficacia de iloperidona en el tratamiento de síntomas psicóticos
WO2009036100A2 (en) 2007-09-10 2009-03-19 Vanda Pharmaceuticals, Inc. Prediction of qt prolongation based on snp genotype
EP2254564A1 (de) 2007-12-12 2010-12-01 Glaxo Group Limited Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin
ES2527515T3 (es) 2007-12-13 2015-01-26 Vanda Pharmaceuticals Inc. Método y composición para tratar una afección mediada por un adrenoceptor alfa
CA2709104C (en) 2007-12-13 2017-06-13 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
US9074255B2 (en) 2009-04-06 2015-07-07 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to QT prolongation
WO2010117943A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
ES2792126T3 (es) 2009-04-06 2020-11-10 Vanda Pharmaceuticals Inc Método de tratamiento basado en polimorfismos del gen KCNQ1
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
IN2014DN08495A (de) * 2012-03-14 2015-05-08 Vanda Pharmaceuticals Inc
CN116211857A (zh) 2015-02-17 2023-06-06 万达制药公司 用于治疗精神分裂症的伊潘立酮
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
EP3322415A4 (de) 2015-07-15 2019-03-13 Axovant Sciences GmbH Diaryl- und arylheteroaryl-harnstoff-derivate als modulatoren des 5-ht2a-serotoninrezeptors zur prophylaxe und behandlung von halluzinationen im zusammenhang mit einer neurogenerativen erkrankung
AU2020225477A1 (en) * 2019-02-21 2021-09-09 Obi Pharma Inc. Methods of making high enantioselective secondary alcohols
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
EP0402644B1 (de) * 1989-05-19 1995-08-16 Hoechst-Roussel Pharmaceuticals Incorporated N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
KR100335169B1 (ko) * 1997-07-03 2002-05-04 야마모토 카즈모토 포화 고리를 갖는 신규한 트리시클릭 화합물 및 이를포함하는 의약 조성물
EP1551393A4 (de) * 2002-07-30 2010-06-16 Peter Migaly Kombinationstherapie gegen depression, prävention von suizid und verschiedener medizinischer und psychiatrischer erkrankungen

Also Published As

Publication number Publication date
JP2015214577A (ja) 2015-12-03
JP2015227368A (ja) 2015-12-17
CY1112039T1 (el) 2015-11-04
JP2013116905A (ja) 2013-06-13
ES2398434T3 (es) 2013-03-19
PT1425272E (pt) 2011-10-19
DK1425272T3 (da) 2011-11-21
PT2305656E (pt) 2013-01-10
HK1156309A1 (en) 2012-09-07
JP2013227335A (ja) 2013-11-07
US8314129B2 (en) 2012-11-20
WO2003020707A1 (en) 2003-03-13
US7977356B2 (en) 2011-07-12
US20050020632A1 (en) 2005-01-27
US20110201646A1 (en) 2011-08-18
JP2005504783A (ja) 2005-02-17
CY1113550T1 (el) 2016-06-22
US20130296366A1 (en) 2013-11-07
ATE518845T1 (de) 2011-08-15
ES2370634T3 (es) 2011-12-21
JP2010100633A (ja) 2010-05-06
ES2398434T8 (es) 2017-10-09
EP1425272A1 (de) 2004-06-09
EP1425272B1 (de) 2011-08-03
DK2305656T3 (da) 2013-02-11
US20090176739A1 (en) 2009-07-09
EP2305656B1 (de) 2012-10-24
EP2305656A1 (de) 2011-04-06

Similar Documents

Publication Publication Date Title
HK1156309A1 (en) Optical isomers of an iloperidone metabolite
RS50624B (sr) Monohidrohloridna so 1-[3-[3-(4-hlorofenil)propoksi]propil]piperidina
NO2015002I2 (no) Ataluren (3-[5-(2-fluorfenyl)-[ 1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
NO20051965D0 (no) Nye piperidinderivater for anvendelse ved behandling av kemokinmedierte sykdomstilstander.
NO20065327L (no) Fremgangsmate for fremstilling av derivarer av 5-'4-(2-hydroksy-propyl)-3,5-dihydro-3H'1, 2,4(triazin-2-yl)-benzamid.
PL1651040T3 (pl) Grzybobójcze trójskładnikowe kompozycje substancji czynnych
NO20050429L (no) Substituert kinolin-CCR5-reseptorantagonister
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
JP2005504783A5 (de)
NO20033732D0 (no) N-substituerte nonaryl-heterosykliske NMDA/NR2B-antagonister
NO20062370L (no) Amidderivater
NO20073366L (no) 1,6-substituert (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-2,5-piperazindionderivater som oksytocinreceptorantagonister for behandling av for tidlige veer, dysmenorri og endometriose
HRP20090281T1 (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
JP2010519243A5 (de)
NZ594765A (en) Anthelmintic agents and their use
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
NO20075022L (no) (7-(2-(4-(3-trifluormetylfenyl)-1,2,3,6-tetrahydropyrid-1-yl)etyl) isokinolinbesylatsalt, fremstilling og terapeutiske anvendelser derav
ATE347550T1 (de) Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
JP2004517151A5 (de)
HK1070363A1 (en) Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serineprotease factor xa
ZA200707888B (en) Process for the preparation of indolone derivative
DE602004009079D1 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
DE50005937D1 (de) 3-(4,5-dihydroisoxazol-5-yl)benzoylpyrazole
PL353977A1 (en) Method of obtaining 4-[1-hydroxy-4-[4-(hydroxydiphenyldimethyl)-1-piperidinylbutyl]-alpha,alpha-dimethylbenzene acetic acid
SE0102809D0 (sv) Novel compounds

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20220829